The development of CRISPR/Cas9 screening technology provides a promising strategy for identifying genes essential for the survival and proliferation of cancer cells, as well as genes contributing to drug resistance.27–29 In the present study, through a genome-wide CRISPR/Cas9 knockout screening, we identified CDC6 as a critical regulator of paclitaxel resistance. This evidence concerns the gene CDC6 and cancer.